Phase 4
Completed N=37
Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Source: ClinicalTrials.gov NCT00621179 ↗Enrolled (actual)
37
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcomePrimary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants
◆ Published Evidence
Emerging
19citations · ~1 / year
Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy?
Summary
This prospective randomized trial evaluates whether one can predict which infertile women with endometriosis who are candidates for in vitro fertilization will benefit from prolonged therapy with a GnRH agonist by the determination of the absence of endometrial expression of the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for in vitro fertilization and then undergo randomization to a three month course of a depot preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian stimulation or standard therapy. prio
Linked Publications
-
Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy?
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patients Who Responded to Controlled Ovarian Hyperstimulation |
7; 5; 3; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Infertility
- Surgical diagnosis of endometriosis
- Normal ovarian reserve testing
- Regular menses
Exclusion Criteria
- Irregular menses
- Undiagnosed abnormal uterine bleeding
- Pregnancy
- Prior adverse reaction to any GnRH agonist
- Ovarian cystic or solid mass > 3cm in mean diameter at study entry
- Use of a depot preparation of a GnRh agonist or any hormonal therapy for endometriosis within 6 months of study entry
- Current hepatic, renal, hematologic or psychiatric disorder
Data sourced from ClinicalTrials.gov (NCT00621179) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.